In statin-treated patients with ASCVD, PCSK9i use was associated with a modestly lower 5-year incidence of new-onset AS, and this findings are hypothesis-generating.
Abstract
Background Atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis (AS) share lipid-related mechanisms. Although statins have not slowed established AS progression in randomized trials, whether proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) are associated with lower incident AS risk remains uncertain. Objectives The objective of the study was to assess the association between PCSK9is use and incident AS in statin-treated patients with ASCVD. Methods Using TriNetX, we conducted a retrospective new-user cohort study of adults aged ≥60 years with ASCVD receiving statins from January 1, 2015, to August 31, 2025. PCSK9is were compared with statin-only users after 1:1 propensity score matching. The primary outcome was new-onset AS within 5 years; secondary outcomes included all-cause mortality, heart failure exacerbation (HFE), and aortic valve replacement. Results After 1:1 matching, 22,924 patients remained in each group. PCSK9is use was associated with a lower risk of AS (HR: 0.87; 95% CI: 0.78-0.97; P = 0.012), all-cause mortality, and HFE. Aortic valve replacement reduction was not significant. Subgroup analyses showed statistically significant interaction was observed only for chronic kidney disease and heart failure. Conclusions In statin-treated patients with ASCVD, PCSK9i use was associated with a modestly lower 5-year incidence of new-onset AS. Large mortality and HFE associations may reflect residual confounding and treatment-selection bias. These findings are hypothesis-generating.
AIM
To evaluate whether the use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) is associated with a reduced 1-year incidence of new-onset heart failure (HF) compared to statins among patients with dyslipidemia.
METHODS
We conducted a retrospective cohort study using the TriNetX global health re...
Jheng-Yan Wu, Keng-Wei Lee, Sheng-Chi Huang et al.· QJM : monthly journal of the...· 0 citations
BACKGROUND
Intracranial atherosclerotic stenosis is a major cause of ischemic stroke with high recurrence rates despite intensive therapy. The efficacy of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) as adjunctive treatment in intracranial atherosclerotic stenosis remains unclear.
METHODS
We cond...
Yi-Ting Pan, Yuan-Hsiung Tsai, Hsu-Huei Weng et al.· Journal of the American Hear...· 0 citations
In both the White population and hypertensive individuals with age below 65 years, statin treatment has demonstrated significant reductions in the incidence of ASCVD events, and Cumulative and time-weighted average RC showed positive but imprecise associations with ASCVD.
Teng Ma, Xiao-Lu Hu, Bo-Hao Xue et al.· Cardiology Plus· 0 citations
SGLT2 inhibitor use was associated with favorable cardiovascular outcomes in patients with moderate-to-severe psoriasis receiving biologic therapy, and these findings support further prospective investigation of SGLT2 inhibitors as a potential strategy for cardiovascular risk reduction in this population.
A. Gotor-Rivera, J. Hernández-Sánchez, E. Chamorro-Jiménez et al.· Actas Dermo-Sifiliográficas· 0 citations
Clinical guidelines, including China-specific recommendations, support the use of PCSK9 inhibitors to lower LDL-C and further reduce CV risk for patients with very-high-risk or high-risk ASCVD.
Yu-Jie Fang· International Journal of Bio...· 0 citations